

1 **Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care:**  
2 **a cross sectional analysis**

3 Vinay Prasad, MD, MPH<sup>1</sup>, Timothée Olivier, MD<sup>1,2</sup>, Emerson Y Chen, MD, MCR<sup>3</sup>, Alyson Haslam, PhD<sup>1</sup>

4 <sup>1</sup>Department of Epidemiology and Biostatistics, University of California San Francisco, 550 16th St, 2nd  
5 Fl, San Francisco, CA 94158, USA

6 <sup>2</sup>Department of Oncology, Geneva University Hospital, 4 Gabrielle-Perret-Gentil Street, 1205, Geneva,  
7 Switzerland

8 <sup>3</sup>Division of Hematology and Oncology, Oregon Health and Science University, Knight Cancer Institute,  
9 Portland, OR, USA

10 \* Corresponding author:

11 Alyson Haslam, PhD

12 Department of Epidemiology and Biostatistics

13 UCSF Mission Bay Campus | Mission Hall: Global Health & Clinical Sciences Building |

14 550 16th St, 2nd Fl, San Francisco, CA 94158

15 email: [alyson.haslam@ucsf.edu](mailto:alyson.haslam@ucsf.edu)

16

17 **Funding:** This project was funded by Arnold Ventures

18 **Competing Interest:** Vinay Prasad's Disclosures; (research funding) Arnold Ventures; (royalties) Johns

19 Hopkins Press, Medscape (honoraria) Grand Rounds/lectures from universities, medical centers, non-

20 profits, professional societies, Youtube, and Substack (consulting); UnitedHealthcare; (speaking fees)

21 Evicore; (other) Plenary Session podcast has Patreon backers. All other authors have no financial nor

22 non-financial conflicts of interest to report.

23

24

25 **Abstract**

26 **Background:** Financial costs from cancer treatment are increasingly recognized, but what has historically  
27 been underrecognized is the time cost of therapy. We sought to estimate the time burden of anti-cancer  
28 drugs approved based on comparisons to best supportive care (BCS), with the assumption that without  
29 this drug, a patient could have been treated with observation, home palliative care or hospice services,  
30 with minimal time seeking medical care. **Methods:** We searched all FDA approvals (2009 - March 2022)  
31 for randomized trials that used BCS as a treatment option for an anti-tumor drug in the metastatic  
32 setting and abstracted data on treatment related activities. We then estimated time spent on these  
33 activities using previously calculated times. **Results:** Of the 13 drugs tested against BSC, nine studies  
34 demonstrated an improvement in median OS (median 2.1 months). The median monthly time spent for  
35 patients in the intervention arm of BSC trials was 15.8 hours. **Conclusion:** Time is a valuable resource for  
36 people who have cancer, but especially for patients who may have few to no remaining treatment  
37 options, and yet, we found that patients can spend up to 16 hours in anti-cancer drug related activities  
38 per month.

39 **Introduction**

40 Cancer drugs may offer benefits, typically improvements in survival and quality of life, but also come  
41 with costs. Financial costs are increasingly recognized,<sup>1</sup> but what has historically been underrecognized  
42 is the time cost of therapy. Patients receiving anti-cancer drugs spend time in transit to doctors' visits,  
43 waiting for the provider, receiving infusions or drawing labs, and performing radiographic imaging,  
44 among other burdens. To date, there have been limited attempts to estimate the time cost of therapies,  
45 often focusing on single cancer histologies.<sup>2,3</sup> We sought to estimate the time burden of anti-cancer  
46 drugs approved based on comparisons to best supportive care (BSC). This permitted us the assumption  
47 that without this drug, a patient could have been treated with observation, home palliative care or  
48 hospice services, with minimal time seeking medical care.

49 **Results**

50 We found 13 approved drugs based on registration trials with BSC (with or without an active  
51 comparator). Eleven were blinded studies and used a placebo plus BSC control arm, and two studies  
52 were open-label and compared a drug to BSC only. The two open-label studies were in the maintenance  
53 setting (avelumab and pemetrexed). Five studies used an IV intervention, and the other eight were  
54 orally administered drugs.

55 Nine studies demonstrated an improvement in median OS (median 2.1 months; Table). Twelve studies  
56 demonstrated an improvement in PFS (median improvement of 1.6 months, with one study where  
57 median PFS was not reached).

58


59 **Table.** Time spent in health-related activities for drugs approved (2009-2022) and tested with best supportive care.

Drug	Tumor type	Median overall survival improvement	Total monthly time (hours)						
			Physical and clinical assessments	Scans	Traveling	Infusion/ taking medication	Patient reported outcome assessment	Health-related activities outside of clinic visits	Total
Cabozantinib	Medullary thyroid	NR	4.0	3.4	5.3	0.2	1.0	4.7	18.6
Avelumab	urothelial	7.1	4.0	0.6	5.3	4.3	1.0	4.7	19.9
Ramucirumab	HCC	1.2	4.0	0.8	5.3	4.3	0.7	4.7	19.8
Trifluridine and tipiracil	gastroesophageal	2.1	2.0	0.6	5.3	0.2	1.0	4.7	13.8
Regorafenib	HCC	2.8	8.0	0.8	10.7	0.2	1.0	4.7	25.3
Everolimus	neuroendocrine	NR	2.0	2.8	2.7	0.2	0.5	4.7	12.8
Trifluridine and tipiracil	CRC	1.8	4.0	0.6	5.3	0.2	1.0	4.7	15.8
Ramucirumab	gastroesophageal	1.4	4.0	0.8	5.3	4.3	0.5	4.7	19.6
Regorafenib	CRC	1.4	4.0	0.6	5.3	0.2	1.0	4.7	15.8
Panitumumab	CRC	2.6	4.0	1.2	5.3	4.3	2.0	4.7	21.5
Pemetrexed	NSCLC	2.8	1.5	1.8	2.0	1.6	0.8	4.7	12.3
Everolimus	RCC	NR	1.5	3.0	2.0	0.2	0.7	4.7	12.0
Pazopanib	RCC	NR	2.0	0.6	2.7	0.2	1.0	4.7	11.1
Median		2.1	4.0	0.8	5.3	0.2	1.0	4.7	15.8

60 NR=not reached or immature

61 The median monthly time spent for patients in the intervention arm of BSC trials was 15.8 hours  
62 (Figure). Traveling (5.3 hours/month) was the most time-intensive trial-related activities, followed by  
63 health-related activities outside of clinic time (4.7 hours/month), and physical/clinical assessments (4  
64 hours/month). Time spent on treatment was the least time-intensive activity (median of 10  
65 minutes/month) since most drugs were orally administered.

66 **Figure.** Percentage of time spent in health-related activities for drugs approved (2009-2022) and tested  
67 with best supportive care.



68  
69 HCC=hepatocellular carcinoma; CRC=colorectal cancer; NSCLC=non-small cell lung cancer; RCC=renal cell  
70 carcinoma

71  
72

### 73 Discussion

74 Our estimates of almost 16 hours each month on treatment-related activities are likely underestimated  
75 due to inability to capture time spent being treated for adverse events.<sup>4</sup> Additionally, these 16 hours  
76 may be distributed over at least 4-5 days per month, leading to fewer treatment-free 'home days'.<sup>5</sup> Time  
77 estimates were based on process mapping via direct observation in oncology clinics and patient surveys  
78 but applied to only the minimal frequency of visits for trial participation. Real-world data indicate that  
79 the frequency of clinic visits is more often than visits for trial assessments outlined in included trial  
80 protocols.<sup>3</sup> One limitation is the few instances of BCS trials (N=13 trials), but this covered 13 years of  
81 FDA approvals.

82 Time is a valuable resource for people who have cancer, but especially for patients who may have few to  
83 no remaining treatment options. We selected trials where BSC was used, with or without an active  
84 comparator, which permitted us the assumption that without the drug, a patient could have spent  
85 minimal time seeking medical care. Indeed, we found that median improvement in OS was two months  
86 for patients on treatment. Patients spent almost 16 hours over a number of days in anti-cancer drug  
87 related activities per month. Future studies should prospectively assess actual time on care, including

88 time for adverse events and hospitalizations for intervention and control arms, and calculate actual  
89 home days gained to further patients' overall quality of life.

## 90 **Methods**

91 In a cross-sectional analysis, we searched all FDA approvals (2009 - March 2022) for randomized trials  
92 that used BCS as a treatment option (control or intervention arm) for an anti-tumor drug in the  
93 metastatic setting. We abstracted study characteristics, including overall survival (OS) and progression-  
94 free survival (PFS) outcomes, open-label or not, intervention type (oral vs. IV), and type and frequency of  
95 assessments. We estimated time spent on trial-related activities (physical and clinical assessments,  
96 traveling, tumor assessments, treatment infusion, if applicable, and patient-reported assessments) for  
97 patients in the intervention trial arm by multiplying previously calculated times by the frequency of  
98 activity listed in the trial protocol.<sup>3</sup>

99 We conducted all analyses using R software, version 3.6.2 and Microsoft Excel. In accordance with 45  
100 CFR §46.102(f), this study was not submitted for institutional review board approval because it involved  
101 publicly available data and did not involve individual patient data. We adhered to STROBE reporting  
102 criteria.

103

104 **Competing Interest:** Vinay Prasad's Disclosures; (research funding) Arnold Ventures; (royalties) Johns  
105 Hopkins Press, Medscape (honoraria) Grand Rounds/lectures from universities, medical centers, non-  
106 profits, professional societies, Youtube, and Substack (consulting); UnitedHealthcare; (speaking fees)  
107 Evicore; (other) Plenary Session podcast has Patreon backers. All other authors have no financial nor  
108 non-financial conflicts of interest to report.

109 **Data availability:** All data for this are publicly available, and sources have been referenced in-text.

110

111

112

113

114

115 **References**

- 116 1. Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: origins, implications,  
117 barriers, solutions. *Nat Rev Clin Oncol*. 2017;14(6):381-390. doi:10.1038/nrclinonc.2017.31
- 118 2. Lim S-A, Hao SB, Boyd BA, et al. Opportunity costs of surgical resection and perioperative  
119 chemotherapy for locoregional pancreatic adenocarcinoma. *JCO Oncol Pract*. Published online  
120 October 28, 2021:OP2100311. doi:10.1200/OP.21.00311
- 121 3. Rocque GB, Williams CP, Ingram SA, et al. Health care-related time costs in patients with  
122 metastatic breast cancer. *Cancer Med*. 2020;9(22):8423-8431. doi:10.1002/cam4.3461
- 123 4. Gupta A, Jensen EH, Virnig BA, Beg MS. Time-Related Burdens of Cancer Care. *JCO Oncol Pract*.  
124 2022;18(4):245-246. doi:10.1200/OP.21.00662
- 125 5. Gupta A, Eisenhauer EA, Booth CM. The time toxicity of cancer treatment. *J Clin Oncol*.  
126 2022;40(15):1611-1615. doi:10.1200/JCO.21.02810

127

128

129

130

131